Your insurer called your treatment "experimental" or "investigational." In many cases, this label is outdated, inaccurate, or legally challengeable. Here's how to fight back with evidence.
Appeal My Experimental Denial →Takes 3 minutes · No login required · Cite peer-reviewed evidence
The gap between what insurers call "experimental" and what the medical community considers established care is often enormous.
Insurers define "experimental" or "investigational" as any treatment that hasn't met their internal evidence review standards. This typically means: not enough published randomized controlled trials, not yet adopted into the insurer's technology assessment database, or used off-label (for a condition not specified in the FDA approval). This definition is often years behind current medical practice.
Many treatments insurers call "experimental" are widely used by specialists, recommended in clinical practice guidelines, supported by extensive peer-reviewed literature, and considered standard of care by the medical community. Proton beam therapy, CAR-T cell therapy, and many cancer immunotherapies were all labeled "experimental" by insurers long after the medical community adopted them.
Treatments frequently denied as experimental include: newer cancer treatments (immunotherapy, targeted therapy, proton therapy), genetic and genomic testing, advanced surgical techniques (robotic surgery, minimally invasive approaches), emerging mental health treatments, and off-label drug use — even when supported by strong evidence and used by leading medical centers.
The most effective way to challenge an "experimental" denial is to show the treatment is not actually experimental — it's established medicine that the insurer's criteria haven't caught up with. Peer-reviewed studies, medical society guidelines, FDA approvals, and expert physician letters all serve to close this gap and demonstrate the treatment is medically necessary and evidence-based.
FDA approval and insurance coverage are two different things. Understanding the distinction is critical for your appeal.
The FDA approves treatments as safe and effective. Insurance companies make separate coverage decisions based on their own criteria. A treatment can be FDA-approved but denied by your insurer as "not meeting their evidence standards." However, FDA approval is strong evidence in your appeal — it's hard for an insurer to call something "experimental" when the federal government has certified it as safe and effective.
Off-label use means using an FDA-approved drug for a condition or in a way not specified in the original approval. Up to 20% of all prescriptions are off-label, and in oncology it's much higher. Many states require insurers to cover off-label drug use when it's supported by recognized drug compendia (like NCCN Drugs & Biologics Compendium, AHFS Drug Information, or Elsevier Gold Standard).
Some states have laws requiring coverage of FDA-approved treatments, particularly for cancer. These laws may require coverage when the treatment is recognized by NCCN guidelines, listed in approved compendia, or supported by peer-reviewed literature in major medical journals. Check your state's specific requirements — they may override the insurer's "experimental" determination.
If you're on Medicare, coverage decisions are guided by National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs). Medicare often covers treatments that private insurers deny as experimental. If Medicare covers a treatment, citing this in your private insurance appeal demonstrates that the federal government considers it established, not experimental.
If you're enrolled in a clinical trial, the ACA guarantees coverage for routine costs. Here's what you need to know.
Under Section 2709 of the ACA, health plans cannot deny coverage for routine patient costs in connection with an approved clinical trial. Routine costs include office visits, lab work, imaging, hospital stays, and other services that would be covered outside the trial. The trial sponsor typically pays for the experimental treatment itself.
The ACA covers trials that are federally funded, conducted under an FDA investigational new drug application (IND), or approved by the NIH. This includes trials listed on ClinicalTrials.gov with federal funding or FDA oversight. The trial must be for cancer or another life-threatening condition and you must be eligible according to the trial protocol.
Insurers cannot deny, limit, or impose additional conditions on coverage solely because you are participating in a clinical trial. They cannot require higher cost-sharing than for equivalent non-trial services, deny coverage for complications arising from trial participation, or drop you from your plan for enrolling in a trial.
If the clinical trial is only available at out-of-network facilities, some insurers must still cover routine costs. The law requires coverage at the same level as if the services were provided in-network. However, travel costs are generally not covered. If your insurer denies routine trial costs, this is a strong basis for appeal and regulatory complaint.
The strongest weapon against an "experimental" denial is published evidence showing the treatment works.
PubMed (pubmed.ncbi.nlm.nih.gov) is the gold standard for medical literature search. It's free and maintained by the National Library of Medicine. Search for your condition and treatment name. Filter for systematic reviews, meta-analyses, and clinical trials. Look for recent publications from the last 5 years that show the treatment's efficacy.
Guidelines from professional medical organizations carry enormous weight in appeals. Check NCCN (National Comprehensive Cancer Network) for cancer treatments, APA for psychiatric treatments, AHA/ACC for cardiac treatments, and relevant specialty societies. If a guideline recommends the treatment, it's hard for an insurer to call it "experimental."
For drug denials, check whether the off-label use is listed in recognized compendia: NCCN Drugs & Biologics Compendium, AHFS Drug Information, Elsevier Gold Standard (formerly Clinical Pharmacology), or Micromedex DRUGDEX. Many state and federal laws require insurers to cover drugs listed in these compendia, even for off-label use.
Ask your treating physician — and ideally a recognized expert in the field — to write a letter explaining why the treatment is established standard of care, not experimental. The letter should reference specific studies, explain the evidence base, and address why the insurer's "experimental" designation is incorrect. Letters from physicians at major academic medical centers carry additional weight.
When an insurer labels a treatment "experimental" or "investigational," they mean it doesn't meet their internal criteria for established, proven therapy. However, this designation is often at odds with medical reality. Many treatments insurers call "experimental" are FDA-approved, recommended by medical guidelines, widely used by specialists, and supported by peer-reviewed literature. The insurer's definition of "experimental" is typically narrower than the medical community's standard of care.
Yes, unfortunately. FDA approval and insurance coverage are separate determinations. An insurer can deny coverage for an FDA-approved drug or device if it's being used "off-label" (for a condition not listed in the FDA approval), if the insurer's utilization criteria require more evidence than FDA approval alone, or if the plan specifically excludes the treatment. However, many states have laws requiring coverage of FDA-approved treatments, especially for cancer, and off-label use supported by recognized compendia.
Under the ACA, most health plans cannot deny coverage for routine patient costs associated with participation in an approved clinical trial. This includes office visits, lab tests, imaging, and hospital stays that would be covered outside the trial. The insurer does not have to pay for the experimental treatment itself (which is typically provided free by the trial sponsor), but they must cover the standard-of-care costs. Some states have additional clinical trial coverage requirements.
Start with PubMed (pubmed.ncbi.nlm.nih.gov), the free database of medical literature maintained by the National Library of Medicine. Search for your specific condition and the treatment name. Look for systematic reviews, meta-analyses, and clinical practice guidelines from recognized medical organizations. Your treating physician can also help identify the most relevant studies. Medical society position statements and NCCN guidelines (for cancer) are particularly powerful evidence in appeals.
Your insurer's criteria may be years behind the science. ClaimBack builds your appeal letter with peer-reviewed evidence, FDA data, clinical guidelines, and the legal citations that challenge the "experimental" label.
Start My Free Appeal →Takes 3 minutes · No login required
ClaimBack provides AI-assisted document drafting. We are not a law firm and do not provide legal advice.